Gélisse, Philippe http://orcid.org/0000-0001-9296-1957
Benbadis, Selim R. http://orcid.org/0000-0003-0214-5492
Crespel, Arielle http://orcid.org/0000-0002-2203-1938
Tatum, William O. http://orcid.org/0000-0002-4536-3791
Article History
Received: 9 April 2024
Revised: 6 May 2024
Accepted: 9 May 2024
First Online: 18 May 2024
Declarations
:
: Dr. Gélisse received support for teaching programs from UCB, Eisai and royalties for publishing from John Libbey Eurotext. Dr. Crespel received support for teaching programs from UCB, Eisai and royalties for publishing from John Libbey Eurotext. She was an advisory board member for Eisai-France. Dr. Benbadis: Consultancy or Advisory Board: Jazz, Livanova, Neurelis, SK life science, Sunovion, Stratus, Takeda, UCB. Speakers bureau: Catalyst, Jazz, LivaNova, Neurelis, SK life science, UCB. Medical Director and Advisory Board for Stratus EEG. Member: Epilepsy Study Consortium. Grant support: Cerevel Therapeutics, Jazz Pharmaceuticals, Eisai, LivaNova, Longboard, Marinus, Neuropace, Ovid/Takeda, SK life science, UCB, Xenon Pharmaceuticals. He receives royalties for publishing from Demos Publishers Inc., Springer Publishing, MedLink, Up-to-date, and honoraria for speaking engagements from the American Academy of Neurology. Dr. Tatum has received a stipend from Elsevier as Editor-in-Chief of Epilepsy Behavior Report. He serves on the editorial board for the Journal of Clinical Neurophysiology and Epilepsy Behavior Reports. He is a consultant for BioSerenity/DigiTrace Care Services, Inc., Neurelis, Natus, and LivaNova and holds patents or patents pending for intraoperative monitoring devices (#62527896; #62770362). He receives royalties for publishing from Demos Publishers Inc., Springer Publishing, Wiley, and MedLink and honoraria for speaking engagements from the American Academy of Neurology, American Epilepsy Society, and American Clinical Neurophysiology Society (ACNS). He has research support from Mayo Clinic, Martin Family Foundation, Eisai Inc., LivaNova, Xenon Pharma, Cerevel Therapeutics, and McElvey Foundation.
: We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.